Skip to main content
S&P 5007,717.03+0.52%DOW52,375.19+0.03%NASDAQ26,453.11+1.08%BTC$80,544.00+0.50%ETH$2,345.35+1.00%GOLD$4,070.30+0.79%OIL$99.97-1.76%
Smart Investors Daily
SID Premium
PS

NASDAQ · PSNL

Personalis, Inc.

Healthcare · Medical - Diagnostics & Research

$15.88

Up+$0.16 (+0.98%)

Updated Oct 27, 2026, 6:33 PM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
824.5M
P/E ratio
-11.15
Dividend yield
0.00%
52-week range
$4.96 – $18.89
Volume
1.14M
Avg. volume
1.34M

Price performance · PSNL

PSNL price history

1M range · 0 trading sessions · Daily adjusted prices

PSNL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest PSNL news

The latest Smart Investors Daily articles mentioning PSNL.

Stock researchCompany · Overview

PSNL research

Overview

Company profile and research snapshot.

Company profile

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.50
Implied upside
—
Analysts
13
PSNL recent ratings
DateFirmRatingTarget
Oct 6, 2026BTIGNeutral—
Jul 20, 2026NeedhamHold—
Jul 20, 2026BTIGBuy—
Jul 20, 2026Lake StreetHold—
Jul 17, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

FREMONT, Calif., October 20, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, includi

Yahoo · Oct 20, 2026

Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years

Personalis has seen a sharp share price reset over the past few years, and the stock now trades at US$15.88, which puts fresh focus on whether that level can be explained by its sales alone. With a long run of volatile returns behind it, the key issue for you is how much revenue the current market value is really assuming. Over the past 3 years the stock has delivered a very large gain of roughly 14x, which means even small changes in sales expectations can have an outsized effect on what...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By